donanemab-azbt
| Brand name | Kisunla |
|---|---|
| Active ingredient | donanemab-azbt |
| Strength | 350MG/20ML (17.5MG/ML) |
| Dosage form | Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | July 2024 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.